Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults

NCT04871113 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT04871113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04871113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2021
Completion date
September 21, 2023
Enrollment
62 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections